Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.

FAMS, and SF-36 MCS and PCS change from baseline scores showed numerical improvements at Year 6 in alemtuzumab-treated patients; however, the differences from baseline did not reach statistical significance or the threshold for clinical relevance ( Figure 1 and Table 2 ).

also in 111,027 other papers